Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001).

Patrick B. Johnston, MD, PhD, Steven M. Ansell, MD, PhD, Joseph P. Colgan, MD, Thomas M. Habermann, MD, David J. Inwards, MD, Ivana N.M. Micallef, MD, Luis F. Porrata, MD, Craig B. Reeder, MD, Vivek Roy, MD, Betsy R. LaPlant, Thomas E. Witzig, MD

Blood (2007) 110 (11): 2555.

https://doi.org/10.1182/blood.V110.11.2555.2555

Published: 2007

Journal Articles

Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas.

Deepti Behl, MD, Kay M. Ristow, RN, Svetomir Markovic, MD, PhD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Joseph P. Colgan, MD, Ivana N.M. Micallef, MD, Patrick B. Johnston, MD, PhD, Stephen Ansell, MD, PhD, Christopher A. Yasenchak, MD, Rajnish Manchanda, MBBS, Luis F. Porrata, MD

Blood (2006) 108 (11): 3878.

https://doi.org/10.1182/blood.V108.11.3878.3878

Published: 2006

Journal Articles

Early Lymphocyte Recovery after Autologous Stem Cell Transplantation Predicts Superior Survival in Mantle Cell Lymphoma.

Cristina Joao, Luis F. Porrata, MD, David J. Inwards, MD, Stephen M. Ansell, MD, PhD, Ivana N.M. Micallef, MD, Patrick B. Johnston, MD, PhD, Dennis A. Gastineau, MD, Svetomir N. Markovic, MD, PhD

Blood (2005) 106 (11): 5466.

https://doi.org/10.1182/blood.V106.11.5466.5466

Published: 2005

Journal Articles

Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.

Christopher A. Yasenchak, MD, Ahmet Dogan, MD, PhD, Joseph P. Colgan, MD, Thomas M. Habermann, MD, David J. Inwards, MD, Patrick B. Johnston, MD, PhD, Svetomir N. Markovic, MD, PhD, Ivana N.M. Micallef, MD, Luis F. Porrata, MD, Thomas E. Witzig, MD, Stephen M. Ansell, MD, PhD

Blood (2005) 106 (11): 938.

https://doi.org/10.1182/blood.V106.11.938.938

Published: 2005

Journal Articles

Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.

Luis F. Porrata, MD, Dennis A. Gastineau, MD, Alvaro Pineda, MD, Jeffrey L. Winters, MD, S. Breanndan Moore, MD, Douglas J. Padley, Kevin L. Bundy, Mark R. Litzow, MD, Ivana N.M. Micallef, MD, David J. Inwards, MD, Stephen M. Ansell, MD, PhD, Morie A. Gertz, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Ayalew Tefferi, MD, Michelle Elliott, MD, William J. Hogan, MD, Suzanne R. Hayman, MD, Svetomir N. Markovic, MD, PhD

Blood (2004) 104 (11): 892.

https://doi.org/10.1182/blood.V104.11.892.892

Published: 2004

Journal Articles

Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma.

Shernan G. Holtan, MD, Luis F. Porrata, MD, David J. Inwards, MD, Stephen A. Ansell, MD, Ivana N.M. Micallef, MD, Mark R. Litzow, MD, Morie A. Gertz, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Dennis A. Gastineau, MD, Ayalew Tefferi, MD, Michelle Elliott, MD, William J. Hogan, MD, Suzanne Hayman, MD, Svetomir N. Markovic, MD

Blood (2004) 104 (11): 2927.

https://doi.org/10.1182/blood.V104.11.2927.2927

Published: 2004

NARROW

mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001).

Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas.

Early Lymphocyte Recovery after Autologous Stem Cell Transplantation Predicts Superior Survival in Mantle Cell Lymphoma.

Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.

Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.

Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001).

Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas.

Early Lymphocyte Recovery after Autologous Stem Cell Transplantation Predicts Superior Survival in Mantle Cell Lymphoma.

Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.

Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.

Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only